Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study

Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study

عرض إصدارات أخرى (1)

<strong>Background</strong> Bisphosphonates are contraindicated in patients with stage 4+ chronic kidney disease. However, they are widely used to prevent fragility fractures in stage 3 chronic kidney disease, despite a lack of good-quality data on their effects. <br> <strong>...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Robinson, DE, Ali, MS, Strauss, VY, Elhussein, L, Abrahamsen, B, Arden, NK, Ben-Shlomo, Y, Caskey, F, Cooper, C, Dedman, D, Delmestri, A, Judge, A, Javaid, MK, Prieto-Alhambra, D
التنسيق: Journal article
اللغة:English
منشور في: National Institute for Health Research 2021

مواد مشابهة

مواد مشابهة